News & Trends - Pharmaceuticals
Medicines Australia welcomes consultation on a national approach to clinical trials
Pharma News: Medicines Australia welcomes the clinical trial ‘one-stop-shop’ consultation, recently announced by the Australian Commission on Safety and Quality in Health Care.
Clinical trials in Australia are a significant enabler for faster access for patients and make an important contribution to the economy but we require a consistent, national approach to remain competitive. This newly launched consultation presents an opportunity to achieve a national, interconnected, rapid and streamlined pathway for attracting clinical trials to our shores.
The COVID-19 pandemic drew the world’s attention to the benefits of clinical trials. These have been well documented, such as job creation, better health outcomes for patients and an increased body of scientific knowledge and medical innovation. In 2019, the biopharmaceutical industry is estimated to have invested over $1 billion in Australia for clinical trials.
Australia has been an attractive environment for clinical trials and R&D, but many large companies stumble at the first hurdle due to the inconsistent processes between the different states and territories.
Last night, Medicines Australia CEO, Elizabeth de Somer, spoke on ABC Nightlife and says that clinical trials remain a crucial path to bring innovative drugs, vaccines and therapies to patients in Australia in a safe and regulated manner.
“Clinical trials are critical for a lot of Australian patients, important for our economy and increase our R&D capabilities. We must make our country a more attractive option for international investment,” she said.
Medicines Australia has been working with the Government to harmonise these arrangements, which were also supported by the Minister for Health, the Hon Greg Hunt MP, during his CEDA address in June last year. Since then, considerable progress has been made on this commitment by The Research & Development Task Force (R&DTF), a multi-sector collaboration between Medicines Australia, AusBioTech and the Medical Technology Association of Australia (MTAA). The one-stop-shop consultation is the next step in this vital work.
Elizabeth was joined on the ABC Nightlife program by clinical trial participant Karen Van Gorp and Professor Meg Jardine, Director of Sydney University Clinical Trials Centre.
A recording of the interview is available on the ABC website.
Digital & Innovation
Medical drone to reduce health equity gaps in rural and remote Australia
A specialised medical drone which increases accessibility to essential health services such as pathology, medicines, and telehealth services in rural […]
MoreNews & Trends - Pharmaceuticals
We’ve spent more on healthcare, but it’s been worth it
Healthcare expenditure is surging, with Australia now allocating approximately one-tenth of its budget to this sector. This financial uptick prompts […]
MoreNews & Trends - Pharmaceuticals
New partnership to raise the bar in precision oncology in Queensland
Pharma News: The Australian Translational Genomics Centre (ATGC) is teaming up with non-profit research organisation Omico and the PrOSPeCT program […]
MoreNews & Trends - Biotechnology
AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm
Biotech News: AusBiotech, the nation’s leading industry body for the biotech sector, has named former leader at Sanofi, Rebekah Cassidy, […]
More